Lorglumide is an antagonist at cholestocystokinin (CCK) receptors; it exhibits antacid, anti-ulcerative, gastrointestinal motility modulating, and anticancer activities. Lorglumide decreases gastrointestinal motility and gastric secretion and is clinically used to treat ulcers, irritable bowel syndrome, constipation, and dyspepsia. Lorglumide also inhibits proliferation of colon cancer cells.
| Purity | ≥98% |
|---|---|
| Formula | C22H31Cl2N2O4Na |
| Formula Wt. | 481.39 |
| Chemical Name | (±)-4-[(3,4-Dichlorobenzoyl)amino]-5-(dipentyl- amino)-5-oxopentanoic acid sodium salt |
| IUPAC Name | sodium;4-[(3,4-dichlorobenzoyl)amino]-5-(dipentylamino)-5-oxopentanoate |
| Synonym | Lorglumide sodium salt |
| Solubility | Soluble in methanol or water. |
| Appearance | White Powder |
| Store Temp | 4°C |
|---|---|
| Ship Temp | Ambient |
| Info Sheet | L5769 Info Sheet PDF |
|---|
González-Puga C, García-Navarro A, Escames G, et al. Selective CCK-A but not CCK-B receptor antagonists inhibit HT-29 cell proliferation: synergism with pharmacological levels of melatonin. J Pineal Res. 2005 Oct;39(3):243-50. PMID: 16150104.
Makovec F, Bani M, Cereda R, et al. Antispasmodic activity on the gallbladder of the mouse of CR 1409 (lorglumide) a potent antagonist of peripheral CCK. Pharmacol Res Commun. 1987 Jan;19(1):41-51. PMID: 3575382.
Makovec F, Bani M, Cereda R, et al. Pharmacological properties of lorglumide as a member of a new class of cholecystokinin antagonists. Arzneimittelforschung. 1987 Nov;37(11):1265-8. PMID: 3440035.
